polycystic ovarian syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Intervention group: Individuals in this group receive a 16-hour intermittent fasting (TRF) for 8 weeks. In the TRF group, individuals are instructed to eat freely between 12:00 and 20:
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: age between 18-40 years old BMI between 25 and 35 Diagnosis of PCOS by a specialist based on the Rotterdam criteria for the first time (new cases) without receiving medical treatment lack of pregnancy or breastfeeding or menopausal lack of night shifts No history of cigarette, alcohol, or drug abuse Inability to fast due to taking medication at night not adherence of specific diets No history of diabetes, hypertension, liver or kidney disorders, cancer, acute or chronic infectious diseases, chronic gastrointestinal diseases, Cushing's disease, acromegaly, or eating disorders.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: Weight measurement at the beginning of the study and after 8 weeks of following the prescribed dietary pattern. Method of measurement: digital weight scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood pressure. Timepoint: the beginning of the study and 8 weeks after intervention. Method of measurement: Measuring blood pressure using a digital sphygmomanometer.;Serum glucose. Timepoint: the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement of fasting serum glucose concentration by spectrophotometry.;Serum insulin. Timepoint: the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement of fasting serum insulin concentration by enzyme-linked immunosorbent assay method.;Glycosylated hemoglobin. Timepoint: the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement of serum glycosylated hemoglobin concentration by enzymatic method.;Serum total cholesterol. Timepoint: the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement of fasting serum total cholesterol concentration by spectrophotometry.;Serum low-density-lipoprotein. Timepoint: the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement of fasting serum low-density-lipoprotein concentration by spectrophotometry.;Serum High density lipoprotein. Timepoint: the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement of fasting serum High-density-lipoprotein concentration by spectrophotometry.;Serum Triglyceride. Timepoint: the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement of fasting serum Triglyceride concentration by spectrophotometry.;Serum total testosterone. Timepoint: the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement of serum total testosterone concentration in the fasting state by enzyme-linked immunosorbent assay.;Serum Luteinizing hormone. Timepoint: the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement of serum Luteinizing hormone concentration in the fasting state b | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNarges Dehghanseresht
Ahvaz University of Medical Sciences
Outcome results
None listed